Lifecore Biomedical (NASDAQ:LFCR) Announces Earnings Results, Misses Estimates By $0.05 EPS

Lifecore Biomedical (NASDAQ:LFCR) released its quarterly earnings results on Thursday. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05), Zacks reports. Lifecore Biomedical had a negative return on equity of 315.23% and a negative net margin of 12.52%.

Lifecore Biomedical Price Performance

LFCR stock traded down $0.39 during midday trading on Thursday, reaching $6.81. The company had a trading volume of 281,149 shares, compared to its average volume of 218,017. Lifecore Biomedical has a 1-year low of $3.68 and a 1-year high of $7.99. The stock has a 50 day moving average price of $6.18 and a 200-day moving average price of $6.24. The company has a debt-to-equity ratio of 9.21, a current ratio of 2.32 and a quick ratio of 1.21. The company has a market capitalization of $252.14 million, a price-to-earnings ratio of -12.16 and a beta of 0.96.

Insiders Place Their Bets

In other news, CEO Paul Josephs purchased 17,000 shares of the business’s stock in a transaction dated Wednesday, January 8th. The stock was bought at an average price of $5.74 per share, with a total value of $97,580.00. Following the acquisition, the chief executive officer now owns 559,717 shares in the company, valued at approximately $3,212,775.58. The trade was a 3.13 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 32.20% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Stephens reaffirmed an “equal weight” rating and set a $6.00 target price on shares of Lifecore Biomedical in a report on Friday, January 3rd.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.